Clinuvel Secures EMA Scientific Advice for Phase III Vitiligo Trial
Clinuvel secures EMA scientific advice for pivotal SCENESSE Phase III vitiligo trial
Clinuvel Pharmaceuticals has received final scientific advice from the European Medicines Agency (EMA) on the design of its pivotal Phase III CUV107 study evaluating SCENESSE (afamelanotide) as a systemic vitiligo treatment. The study will compare SCENESSE with adjunct narrowband ultraviolet B (NB-UVB) therapy versus NB-UVB monotherapy alone in 300 adults and adolescents with non-segmental vitiligo, with commencement scheduled for 2H 2026.
Following over 12 months of interaction, two formal submissions, and a Discussion Meeting with the EMA’s Scientific Advice Working Party (SAWP), the Committee for Medicinal Products for Human Use (CHMP) has issued comprehensive guidance on Clinuvel’s vitiligo programme. Significantly, the EMA will apply a “totality of evidence” approach when evaluating efficacy, considering the primary endpoint alongside patient reported outcomes and clinical data from other SCENESSE vitiligo studies.
The regulatory clarity provided by this final scientific advice reduces development risk and establishes a defined pathway toward marketing authorisation submission for the vitiligo indication.
When big ASX news breaks, our subscribers know first
What is vitiligo and why does a systemic treatment matter?
Vitiligo is a multifactorial disorder believed to involve immune components in some cases, resulting in progressive loss of skin pigment (melanin) with severe quality of life impact. The condition affects an estimated 0.5% to 2% of the general population globally, representing a substantial patient base with limited treatment options.
Currently, no approved therapies exist for patients with extensive depigmentation affecting more than 10% of total body surface area. The EMA has advised that patients of darker skin colours (Fitzpatrick skin types IV, V, and VI) would benefit from systemic treatment first, since the visibility of disease is most pronounced in these groups due to the contrast between unaffected skin and vitiligo lesions.
The absence of approved alternatives for extensive disease positions SCENESSE as a potential first-in-class therapy addressing a significant unmet medical need.
EMA’s “totality of evidence” regulatory framework
The EMA’s “totality of evidence” approach means regulators will evaluate the primary endpoint alongside patient reported outcomes and clinical data from other SCENESSE vitiligo studies when assessing marketing authorisation. This framework acknowledges the multifaceted nature of vitiligo treatment success.
Photographic evidence of change from baseline will assess both primary and secondary endpoints. The primary endpoint, T-VASI50, measures the proportion of patients achieving 50% or more repigmentation of the total body excluding hands and feet. The secondary endpoint, F-VASI75, measures the proportion of patients achieving 75% or more repigmentation of the head and neck (excluding lips) and excluding hands and feet.
The EMA has emphasised that patient perception of visible pigmentation change will play an important role in final evaluation. Five patient and physician surveys are integrated into the study design to record Patient Reported Outcomes, ensuring both objective clinical measures and subjective quality of life improvements are captured.
| Endpoint | Definition | Role |
|---|---|---|
| T-VASI50 | 50%+ repigmentation of total body (excluding hands/feet) | Primary |
| F-VASI75 | 75%+ repigmentation of head/neck (excluding lips, hands/feet) | Secondary |
Director commentary on regulatory progress
Dr Emilie Rodenburger, Clinuvel’s Director of Global Clinical Affairs, highlighted the significance of the EMA’s engagement with the SCENESSE vitiligo programme. A major step forward was the SAWP’s request to access photographic changes of vitiligo patients receiving treatment, which demonstrated visual improvement in pigmentation.
Dr Emilie Rodenburger, Director of Global Clinical Affairs
“The dialogue took one year but eventually resulted in a one-off position taken by the Agency, who are now fully across the SCENESSE programme and possible expected outcomes in vitiligo.”
Dr Emilie Rodenburger, Director of Global Clinical Affairs
“The Discussion Meetings provided three take aways: the patient population of darker skin complexion will be the first to benefit from a systemic treatment, the design of the study and, significantly, the ‘totality of evidence’ approach which will be taken during final evaluation of evidence submitted to the EMA.”
The regulatory dialogue confirmed three critical elements: the target patient population (darker skin complexions as first beneficiaries), agreement on study design, and establishment of the “totality of evidence” evaluation framework.
CUV107 study design and next steps
The CUV107 study will evaluate SCENESSE plus NB-UVB phototherapy versus NB-UVB monotherapy as the comparator arm. Central photographic review and validated disease assessment tools have been agreed with the EMA, providing standardised methodology for efficacy evaluation across study sites.
Key study parameters include:
- Study arms: SCENESSE + NB-UVB versus NB-UVB monotherapy
- Patient enrolment: 300 adults and adolescents with non-segmental vitiligo
- Commencement: 2H 2026
- Assessment tools: Central photographic review, validated disease scoring, five integrated patient and physician surveys
Scientific advice from the EMA is non-binding but represents good regulatory practice and will be documented in the final European Public Assessment Report (EPAR) issued at the conclusion of marketing authorisation evaluation. The comprehensive guidance received reduces protocol uncertainty and establishes clear success criteria for the Phase III programme.
The defined study structure and regulatory alignment provide investors with a trackable development timeline and measurable milestones through to potential European approval.
The next major ASX story will hit our subscribers first
Clinuvel’s position in the vitiligo treatment landscape
SCENESSE is currently approved for commercial distribution in Europe, the USA, Israel, and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The vitiligo indication represents a significant market expansion opportunity beyond the rare disease EPP population.
As pioneers in photomedicine and the family of melanocortin peptides, Clinuvel has established expertise in developing treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, and repigmentation. The company’s research and development focus has centred on genetic, metabolic, systemic, and life-threatening acute disorders where patients lack alternative treatment options.
Successful Phase III results and regulatory approval for vitiligo would expand SCENESSE’s addressable market substantially. With vitiligo affecting up to 2% of the global population compared to the ultra-rare EPP indication, the commercial opportunity represents a material step-change in the drug’s revenue potential.
Clinuvel is listed on the ASX (CUV), Börse Frankfurt (UR9), and trades as an ADR Level I (CLVLY), providing international investor access across multiple markets.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX biotech and healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment market-moving announcements drop.